Advertisement

 

 

Challenges of running a GMP facility for regenerative medicine in a public hospital.

Challenges of running a GMP facility for regenerative medicine in a public hospital.
Author Information (click to view)

Viganò M, Giordano R, Lazzari L,


Viganò M, Giordano R, Lazzari L, (click to view)

Viganò M, Giordano R, Lazzari L,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Regenerative medicine 2017 11 0812(7) 803-813 doi 10.2217/rme-2017-0051
Abstract

Advanced therapy medicinal products represent a new generation of medicinal products for regenerative medicine. Since the implementation of the EU regulation for this innovative class of drugs, the academic and hospital institutions have played a central role in their development and manufacture. For these institutions that are not familiar with the industrial context, being in compliance with the pharmaceutical standards is extremely challenging. This report describes how we dealt with some specific issues during our hospital-based GMP experience. Furthermore, we identify as a future perspective the consistent stimulating contribution that a public entity can ensure for advanced therapy medicinal product development and licensing.

Submit a Comment

Your email address will not be published. Required fields are marked *

18 − 15 =

[ HIDE/SHOW ]